ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Neurology of Menopause.Current neurology and neuroscience reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The association between antiseizure medications (ASMs) and bone disorders remains inadequately investigated despite growing concern about drug-induced bone adverse events (AEs). We analyzed data from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004-Q2 2025), identifying 7688 reports of bone health-related AEs listing ASMs as primary suspect drugs. Disproportionality analysis was performed using the reporting odds ratio (ROR) for signal detection. Subsequently, network pharmacology was applied to explore underlying biological pathways. Finally, two-sample Mendelian randomization (MR) was conducted to estimate potential causal associations between ASM-related gene targets and bone health outcomes. Disproportionality analysis revealed significant associations between ASMs and several bone health-related AEs, including increased blood alkaline phosphatase, ankle fracture, vitamin D deficiency, craniofacial fracture, cervical vertebral fracture, and skull fracture. Significant associations of bone health were identified for traditional enzyme-inducing ASMs, including carbamazepine, phenytoin, and phenobarbital, and newer agents, including perampanel, brivaracetam, lacosamide, and zonisamide. Pathway analysis predicted calcium and MAPK signaling. MR revealed genetically predicted effects of CAT, TNFRSF9, and USP48 on osteoporosis and of MGP, MFN2, PLOD1, and TNFRSF9 on ankle fracture. By integrating real-world pharmacovigilance with genetic insights, this study characterizes the associations between both conventional and newer ASMs and adverse bone health outcomes, mechanistically implicating the role of Calcium and MAPK signaling pathways. Furthermore, we identified several key regulatory genes.
Indexed as
Identifiers
41689598What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.